Arrowhead Research ARWR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's cash & equivalents?
- Arrowhead Research (ARWR) reported cash & equivalents of $188.52M in Q1 2026.
- How has Arrowhead Research's cash & equivalents changed year-over-year?
- Arrowhead Research's cash & equivalents increased by 1.5% year-over-year, from $185.71M to $188.52M.
- What is the long-term trend for Arrowhead Research's cash & equivalents?
- Over 5 years (2020 to 2025), Arrowhead Research's cash & equivalents has grown at a 9.5% compound annual growth rate (CAGR), from $143.58M to $226.55M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has on hand.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and a stronger buffer for R&D, while a decrease may indicate high cash burn rates or a need for capital raising.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances to fund multi-year clinical trials, often comparing this to their monthly cash burn rate.